We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Diagnostic Urine Test Developed for Gastric Cancer

By LabMedica International staff writers
Posted on 17 May 2011
A test has been developed that measures a protein excreted into the urine as a biomarker for stomach cancer. More...


The noninvasive test has identified certain proteins that are indicative of gastric cancer and the detection of abnormally abundant proteins in urine will lead to diagnosis of many types of cancer and other diseases.

Scientists at the University of Georgia, (Athens, GA, USA), began by studying a set of 1,500 proteins known to be excreted in urine and identified a list of features that distinguish them from proteins that are not excreted into urine. Identifying these distinguishing features allowed them to develop a classification system that could predict which proteins in cancerous tissues are excreted into urine. They used microarrays-chips that contain nearly 20,000 human genes to identify which proteins varied in abundance in the cancerous versus noncancerous tissues.

The investigators then identified proteins corresponding to those genes that appeared at significantly different levels in the cancer and noncancer samples. From there, they were able to determine which of the abnormally abundant proteins were secreted into the blood and then excreted in urine using the classification method they developed. They identified a protein called endothelial lipase that differed significantly in its abundance in urine samples of stomach cancer patients versus healthy people. Of the 21 urine samples of healthy people, only two did not have the protein. In the 21 urine samples of stomach cancer patients, only one sample was considered to have a relatively high level of the protein and the levels in the rest were low or absent. The study found that the classification system was more than 80% accurate when using samples from already known excretory and nonexcretory proteins. Although the test is not yet 100% accurate, it can lead at-risk patients to seek a more comprehensive examination.

Ying Xu, PhD, lead author of the study, said, "We should be able to develop a method where urine can change the color of a piece of paper to indicate the presence or absence of the protein, similar to the way a home pregnancy test works. A person could go get a urine test, and if the marker protein is present, then they are generally stomach-cancer free. If the protein is not present, we might suggest that they get their stomach checked." The study was published on February 18, 2011, in the online journal Public Library of Science One.

Related Links:
University of Georgia



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.